8-K: Mirum Pharma Reports Strong Q3 2025, Raises Revenue Guidance

Mirum Pharmaceuticals announced robust third-quarter 2025 financial results, including significant revenue growth and an updated full-year revenue guidance, alongside pipeline advancements.

Summary

• Third quarter 2025 total revenue reached $133.0 million, a substantial increase from $90.4 million in the third quarter of 2024.
• Full-year 2025 revenue guidance has been updated to a range of $500 million to $510 million.
• LIVMARLI net product sales for Q3 2025 were $92.2 million, demonstrating 56% growth compared to Q3 2024.
• Bile Acid Medicines net product sales for Q3 2025 were $40.8 million, reflecting 31% growth over Q3 2024.
• Net income for the third quarter of 2025 was $2.905 million, a significant improvement from a net loss of $14.235 million in Q3 2024.
• Cash, cash equivalents, and investments totaled $378.0 million as of September 30, 2025, up from $292.8 million at December 31, 2024.
• Enrollment is complete for the Volixibat VISTAS study in primary sclerosing cholangitis (PSC), with topline data anticipated in the second quarter of 2026.
• A Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) has been initiated.

Sentiment

Score: 8

Explanation: The company reported strong financial results with significant revenue growth, a shift to net income for the quarter, and an increased revenue guidance. Pipeline progress is also positive with study enrollments completed and a new study initiated. The overall outlook is very positive.

Positives

• Significant increase in total revenue for Q3 2025 to $133.0 million from $90.4 million in Q3 2024.
• Strong 56% growth in LIVMARLI net product sales, reaching $92.2 million in Q3 2025.
• Solid 31% growth in Bile Acid Medicines net product sales, totaling $40.8 million in Q3 2025.
• Updated full-year 2025 revenue guidance to $500 million to $510 million, indicating confidence in continued commercial performance.
• Achieved net income of $2.905 million in Q3 2025, a positive turnaround from a net loss of $14.235 million in Q3 2024.
• Increased cash, cash equivalents, and investments to $378.0 million as of September 30, 2025, from $292.8 million at December 31, 2024, strengthening financial position.
• Completed enrollment in the Volixibat VISTAS study for PSC, moving closer to key data readout.
• Initiated a Phase 2 study for MRM-3379 in Fragile X Syndrome, expanding the pipeline.

Negatives

• Total operating expenses increased to $130.4 million in Q3 2025 from $103.1 million in Q3 2024.
• Non-cash stock-based compensation, intangible amortization, and other non-cash expenses increased to $24.0 million in Q3 2025 from $18.0 million in Q3 2024.
• Year-to-date net loss remains at $17.633 million as of September 30, 2025, despite quarterly profitability.

Risks

• Risks and uncertainties associated with the company's business in general and drug development and commercialization in particular.
• Impact of geopolitical and macroeconomic events.

Future Outlook

Mirum Pharmaceuticals anticipates continued strong commercial momentum and multiple upcoming catalysts heading into 2026. The company updated its full-year 2025 revenue guidance to $500 million to $510 million. Key pipeline readouts are expected, including topline data for the Volixibat VISTAS study in PSC in the second quarter of 2026, and topline data for the Volixibat VANTAGE study in PBC and LIVMARLI EXPAND Phase 3 study in the first half of 2027.

Management Comments

• "Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts."
• "Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance."
• "We also made important progress across the pipeline, including completing enrollment in the VISTAS PSC study, maintaining momentum in VANTAGE and EXPAND, and initiating our Phase 2 study in Fragile X Syndrome."

Industry Context

The biopharmaceutical industry continues to see strong demand for treatments addressing rare diseases, particularly those with high unmet medical needs like cholestatic liver conditions and neurocognitive disorders. Mirum's focus on these areas with its approved IBAT inhibitors (LIVMARLI) and pipeline candidates (Volixibat, MRM-3379) positions it within a growing segment. The strong commercial performance of LIVMARLI and Bile Acid Medicines suggests effective market penetration and patient adoption in its niche, aligning with the broader trend of increasing investment and innovation in orphan drug development.

Comparison to Industry Standards

• Mirum's 56% growth in LIVMARLI net product sales and 31% growth in Bile Acid Medicines net product sales for Q3 2025 demonstrate robust commercial execution, often exceeding typical growth rates for established rare disease therapies, especially considering the competitive landscape in liver diseases.
• The company's pipeline progress, including the completion of enrollment for the Volixibat VISTAS study and initiation of a Phase 2 study for MRM-3379, indicates a healthy R&D engine, comparable to other mid-cap biopharmaceutical companies actively expanding their therapeutic portfolios.
• Achieving net income in Q3 2025, a turnaround from a net loss in the prior year, suggests improving operational efficiency and commercial scale, a positive indicator when compared to many development-stage biotechs that often remain unprofitable for longer periods.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, revenue growth, updated guidance, and pipeline advancements, potentially leading to increased share value.
• Patients: Continued progress in clinical trials for rare diseases like PSC, PBC, and Fragile X Syndrome offers hope for new treatment options.
• Employees: Strong company performance and pipeline expansion may indicate job security and growth opportunities.
• Customers (Healthcare Providers): Continued availability and strong performance of approved medicines like LIVMARLI, CHOLBAM, and CTEXLI.

Next Steps

• Host a conference call on November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to provide business updates.
• Anticipate topline data from the Volixibat VISTAS study in PSC in the second quarter of 2026.
• Expect completion of enrollment for the Volixibat VANTAGE study in PBC and the LIVMARLI EXPAND Phase 3 study in 2026.
• Anticipate topline data from the Volixibat VANTAGE study in PBC and the LIVMARLI EXPAND Phase 3 study in the first half of 2027.

Key Dates

Recommendation

The company demonstrated robust financial performance in Q3 2025, marked by substantial revenue growth, a positive shift to net income, and an upward revision of full-year revenue guidance. This commercial momentum, coupled with significant progress in its late-stage pipeline, including completed enrollments and new study initiations, indicates strong operational execution and future growth potential. The increased cash position further strengthens its financial health. These factors collectively present a compelling investment case for a seasoned investor.

Keywords

Mirum Pharmaceuticals, MIRM, Q3 2025, financial results, revenue guidance, LIVMARLI, maralixibat, Volixibat, primary sclerosing cholangitis, PSC, primary biliary cholangitis, PBC, Fragile X Syndrome, FXS, rare diseases, cholestatic pruritus, Alagille syndrome, PFIC, bile acid synthesis disorders, CHOLBAM, CTEXLI, cerebrotendinous xanthomatosis, CTX, biopharmaceutical, clinical trials, pipeline